Serenity's Lead Therapeutic: SER-101
From our StressTek™ platform, we've identified SER-101 as our top therapeutic candidate for SLE.
In SLE, antigen presenting cells (APCs) mis-recognize self-antigens, activate auto-reactive Th17 and Th1 cells, which further activate B cells to produce anti-self antibodies. Immune complexes with self-antigens cause damage through inflammation in multiple organs.
SER-101 induces immune tolerance in antigen presenting cells thereby preventing damage caused by auto-reactive T cells and B cells.
Demonstrated in multiple pre-clinical models
SER-101's anti-inflammatory effects have been demonstrated in multiple pre-clinical models. In addition to Lupus, SER-101 has demonstrated potential benefit for multiple sclerosis, inflammatory bowel syndrome, and COPD.
Disease
Multiple Sclerosis
Inflammatory Bowel Syndrome
Stroke
Lupus
COPD
Model
EAE
DSS & TNBS-induced colitis
Filament occlusion
MRL/MpJ-Fas
Smoke induced
lpr
A Differentiated Mechanism
SER-101 has a multi-faceted mechanism to exert immune tolerance. The primary driver for inducing immune tolerance relies on innate and scavenger receptors found on APCs.
In APCs, we've observed up-regulation of a network of genes for immune tolerance, notable among them are PD-L1 and IL-10. Further, we detected the activation of CD25+FoxP3+ T cells when naive T cells are exposed to SER-101-treated dendritic cells (DCs).
Disease State
SER-101
